Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Thyroxine 5'-deiodinase (DIO3) is an enzyme that inactivates thyroid hormones by catalyzing the removal of an iodine atom from the inner ring of T4 and T3. It is highly expressed in the placenta, fetal tissues, and neonatal tissues, playing a critical role in regulating thyroid hormone levels during development. By converting T4 to rT3 and T3 to T2, DIO3 prevents premature exposure of developing tissues to excessive thyroid hormone concentrations.
Catalyzes the inner ring deiodination of thyroxine (T4) and triiodothyronine (T3), converting them into inactive metabolites (rT3 and T2 respectively).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Thyroxine 5'-deiodinase (DIO3).